Please login to the form below

Not currently logged in
Email:
Password:

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology at ASCO: survival data, combinations and new indications

Immuno-oncology at ASCO: survival data, combinations and new indications

have an impact on the fortunes of established and emerging cancer drugs and their developers. ... in small-cell lung cancer, gastric or gastroesophageal junction (G/GEJ) cancer and Merkel cell carcinoma.

Latest news

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    CHMP meeting round-up. Among other highlights the CHMP backed two biosimilar medicines - Amgen’s Kanjinti version of Roche’s Herceptin (trastuzumab) for the treatment of breast and gastric cancer and ... It also gave its blessing to Clovis

  • Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

    Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal. ... Additionally Herzuma was also recommended for patients with metastatic breast cancer and metastatic gastric cancer in adults.

  • MSD launches EU’s first biosimilar Herceptin in UK MSD launches EU’s first biosimilar Herceptin in UK

    The first biosimilar version of Roche’s blockbuster breast cancer drug Herceptin has been launched in the UK by MSD under the Ontruzant brand name. ... Ontruzant was approved by the EMA last November for the full range of registered indications for

  • Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

    Bavencio (avelumab) failed to improve overall survival compared to standard chemotherapy when given as a third-line treatment to patients with advanced gastric cancer in the JAVELIN Gastric 300 trial. ... Gastric cancer in the third-line setting is a

  • First Herceptin biosimilar cleared in Europe First Herceptin biosimilar cleared in Europe

    Samsung Bioepis has claimed the distinction of getting the first biosimilar of Roche’s $6.8bn breast cancer blockbuster Herceptin in the EU. ... breast cancer, metastatic breast cancer and metastatic gastric cancer.

More from news
Approximately 4 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast / gastric cancer.

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... in breast and gastric cancer.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    100. Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma. Exclusive licensing agreement for Europe and Japan. ... 100+. ACT Biotech/ Eddingpharm. Acquisition. Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics